Back to search results

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

ARB · BVMD · Autosomal-Dominant Bestrophinopathy · Best Vitelliform Macular Dystrophy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Children's Hospital Los Angeles, Los Angeles, California, United States

    Contact: Study coordinator (Hillary Schwartz-Gale) · hschwartz@chla.usc.edu · 323-361-1004
    Contact: Principal Investigator (Aaron Nagiel, MD)

  • Vitreo Retinal Associates, Gainesville, Florida, United States

    Contact: Study coordinator (Hailey Ahrens) · hailey@vra-pa.com · 352-300-4212
    Contact: Principal Investigator (Christine Kay, MD)

  • Cincinnati Eye Institute, Cincinnati, Ohio, United States

    Contact: Study coordinator (Cincinnati Eye Institute Clinical Research Department) · cvp-research@cvphealth.com · 513-569-3688
    Contact: Principal Investigator (Robert Sisk, MD)

  • Retina Foundation of the Southwest, Dallas, Texas, United States

    Contact: Study coordinator (Kaylie Jones, MS) · kwebb@retinafoundation.org · 214-363-3911
    Contact: Principal Investigator (Mark Pennesi, MD)
View source on ClinicalTrials.gov(opens in a new tab)